Cisplatin and Vindesine Combination Chemotherapy for Advanced Carcinoma of the Lung: A Randomized Trial Investigating Two Dosage Schedules
Richard J. Gralla, Ephraim S. Casper, David Paul Kelsen et al. · Annals of Internal Medicine · 1981
Eighty-five patients with advanced squamous carcinoma or adenocarcinoma of the lung were randomly assigned to receive vindesine with either high dose (120 mg/m2 of body surface area) or low dose (60 mg/m2) cisplatin. All patients had measurable disease and had not previously received chemotherapy. The response rate was similar with both treatments (43% complete and partial remission rate), but the high dose cisplatin regimen was superior to the low dose in median duration of response (12 versus 5.5 months; p = 0.05) and in median survival for responding patients (21.7 versus 10 months; p = 0.02). Myelosuppression was generally not a treatment problem; peripheral neuropathy and moderate azotemia were the major dose-limiting toxicities. With improved survival and response rates over those reported for conventional regimens, this combination of new agents supports the approach of new drug investigation in patients with lung cancer and the importance of the incorporation of active new agents into initial chemotherapy regimens.
Cited by 364 works. doi:10.7326/0003-4819-95-4-414
Authors
- Richard J. Gralla
- Ephraim S. Casper
- David Paul Kelsen
- David W. Braun
- M Dukeman
- Nael Martini
- Charles W. Young
- Robert B. Golbey
References
- Nonparametric Estimation from Incomplete Observations
- The clinical evaluation of chemotherapeutic agents in cancer
- 352. Note: Conservatism of the Approximation Σ(O - E) 2 /E in the Logrank Test for Survival Data or Tumor Incidence Data
- High dose Cis-platinum diammine dichloride.Amelioration of renal toxicity by mannitol diuresis
- Results of surgical treatment in Stage I lung cancer
- Vinblastine in Neoplastic Disease Midwest Cooperative Chemotherapy Group
- Vincristine treatment of advanced cancer: a cooperative study of 392 cases.
- Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP)--effective four-drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma.
- Clinical studies of vinblastine.
- Immediate (type I) allergic responses to platinum compounds